Sweden adds metachromatic leukodystrophy to newborn screening

Sweden is introducing screening for metachromatic leukodystrophy (MLD) for all newborns following a recommendation from Socialstyrelsen, the Swedish National Board of Health and Welfare. MLD is a rare disorder that causes severe nervous system damage, major disability and premature death. The screening expansion aims to identify affected children before symptoms or irreversible neurological injury develop.

On average, one to two children with MLD are born in Sweden each year, according to the agency. Until now, opportunities for early detection have mainly involved families in which a sibling already has a diagnosis. Newborn screening is intended to extend early identification to children without a known family history.

Socialstyrelsen links the screening decision to the availability of stem cell-based gene therapy, which it describes as capable of stopping the disease when administered before irreversible damage occurs. The announcement is a screening-policy update rather than a clinical study: it provides no screening performance measures, treatment outcome data or details of eligibility and confirmatory testing pathways.